Adoxorubicin clinical trials
Also written INNO-206 and Aldoxorubicin.
How each study uses adoxorubicin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2012 (4)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 4 |
| 2014 | 3 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
ImmunityBio, Inc. (9) · CytRx (1)
Studies
Open first, then newest update. How each study uses adoxorubicin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung CancerCompletedPhase 2ImmunityBio, Inc.NCT02200757Written as AldoxorubicinHow we know
- Phase 3 Study to Treat Patients With Soft Tissue SarcomasCompletedPhase 3ImmunityBio, Inc.NCT02049905Written as AldoxorubicinHow we know
- Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic CancerCompletedPhase 2ImmunityBio, Inc.NCT01580397Written as INNO-206How we know
- Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With GlioblastomaCompletedPhase 2ImmunityBio, Inc.NCT02014844Written as 250 mg/m2 aldoxorubicinHow we know
- Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue SarcomaCompletedPhase 2ImmunityBio, Inc.NCT01514188Written as INNO-206How we know
- Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid TumorsCompletedPhase 1ImmunityBio, Inc.NCT01706835Written as aldoxorubicinHow we know
- Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid TumorsCompletedPhase 1ImmunityBio, Inc.NCT01673438Written as aldoxorubicinHow we know
- Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid TumorsCompletedPhase 1ImmunityBio, Inc.NCT02235688Written as aldoxorubicinHow we know
- Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid TumorsCompletedPhase 1ImmunityBio, Inc.NCT01337505Written as INNO-206How we know
- INNO-206 in Patients With Small Cell Lung Cancer (SCLC)WithdrawnPhase 2CytRxNCT00472771Written as INNO-206How we know
Given beside what is tested · 8 — adoxorubicin is usual care or a partner of the new treatment
- Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingPhase 2ImmunityBio, Inc.NCT04390399Written as Aldoxorubicin HClHow we know
- QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnPhase 2ImmunityBio, Inc.NCT03563144Written as Aldoxorubicin HClHow we know
- QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerWithdrawnPhase 2ImmunityBio, Inc.NCT03574649Written as AldoxorubicinHow we know
- QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineWithdrawnPhase 2ImmunityBio, Inc.NCT03554109Written as Aldoxorubicin HClHow we know
- QUILT-3.080: NANT Pancreatic Cancer VaccineTerminatedPhase 1/2ImmunityBio, Inc.NCT03586869Written as Aldoxorubicin HClHow we know
- QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.TerminatedPhase 1/2ImmunityBio, Inc.NCT03387085Written as Aldoxorubicin HClHow we know
- QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedPhase 1/2ImmunityBio, Inc.NCT03387111Written as Aldoxorubicin HClHow we know
- QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedPhase 1/2ImmunityBio, Inc.NCT03387098Written as Aldoxorubicin HClHow we know
Codes
What other systems call adoxorubicin · ClinicalTrials.gg INT006159
- UNII (FDA) C28MV4IM0BALDOXORUBICINConfirmed FDA, NLM, Wikidata
- Wikidata Q19903239adoxorubicinConfirmed FDA, NLM, Wikidata
- DrugBank DB06013One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | C28MV4IM0B | ALDOXORUBICIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q19903239 | adoxorubicin | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB06013 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.